This is an automatically translated article.
Rabeto 40 is a proton pump inhibitor (PPI), which reduces gastric acid secretion. The drug is indicated for the treatment of gastroesophageal reflux syndrome with or without ulceration or ulceration (GERD), acute peptic ulcer.1. What is Rabeto 40mg?
What is Rabeto 40mg? Rabeto 40 is a drug whose main active ingredient is Rabeprazole sodium, which is prepared in the form of enteric-coated tablets with a strength of 40mg. Rabeprazole is a benzimidazole derivative, belonging to the class of antisecretory compounds with proton pump inhibitory effects. Rabeprazole has no anticholinergic or histamine H2 receptor antagonist properties. Rabeprazole inhibits gastric secretion, both basal and stimulated, by inhibiting the enzyme H+ /K+ -ATPase in the parietal cells of the gastric mucosa. The enzyme H+ /K+ -ATPase is considered to be the acid, hydrogen or proton pump in parietal cells, Rabeprazole is identified as a gastric proton pump inhibitor. Rabeprazole binds to this enzyme and blocks the final step of gastric acid secretion.
In the parietal cells of the stomach, rabeprazole is protonated and converted to the active sulfenamide, which then binds to the proton pump cysteine, inactivating this enzyme.
2. Indications and contraindications of Rabeto - 40
2.1 Indications of Rabeto - 40 Treatment of Gastroesophageal Reflux Syndrome (GERD) with or without inflammation, abrasions or ulcers: Rabeto - 40 is indicated for the short-term treatment of about 4 to 4 days. 8 weeks, to heal and improve symptoms of gastroesophageal reflux disease - erosive or ulcerative esophagitis (GERD). The drug is indicated for adults and children over 12 years old. In the event that the patient is not in remission after 8 weeks of treatment, consider an additional course of Rabeto 40 for the next 8 weeks. Maintenance treatment in gastroesophageal reflux syndrome with or without inflammation, abrasion, or ulceration (GERD): Rabeto-40 is indicated to maintain healing and reduce the recurrence rate of heartburn symptoms. in patients with erosive or ulcerative gastroesophageal reflux syndrome (GERD). The duration of maintenance therapy should not exceed 12 months. Treatment of acute duodenal ulcer disease: Rabeto-40 is indicated in acute duodenal ulcer to help heal and improve symptoms of duodenal ulcer. The drug is usually indicated for short-term treatment, within 4 weeks. Acute gastric ulcer Pathological hypersecretory disease, Zollinger-Ellison syndrome. In addition, the drug is also combined with appropriate antibiotics in the treatment of Helicobacter pylori in patients with duodenal ulcer.
2.2 Contraindications of Rabeto 40 The use of Rabeto 40 is contraindicated in the following cases:
Allergy or hypersensitivity to Rabeprazole, Benzimidazole derivatives or any of its ingredients. Pregnant women.
3. How to take Rabeto 40
Rabeto 40 is taken orally. Patients should pay attention not to chew, crush or crush the tablet, must take the tablet in its intact form. Rabeto-40 to take before or after meals? Rabeto 40 should be taken 30 minutes before meals for the best effect.
3.1 Rabeto 40 Dosage: Treatment of gastroesophageal reflux disease (GERD) with inflammation, abrasions or ulcers: Adults: 1 tablet / time x 1 time / day, used for 4-8 weeks. If symptoms do not improve after 8 weeks of treatment, an additional 8-week course may be considered; Children over 12 years old: 1 tablet/time x 1 time/day, use up to 8 weeks. Maintenance treatment in gastroesophageal reflux syndrome - oesophagitis with or without inflammation, abrasions or ulcers (GERD): Adults: 1 tablet x 1 time/day, lasting no more than 12 months. Treatment of acute duodenal ulcer disease: Adults: 1 tablet/time x 1 time/day after breakfast, up to 4 weeks. Most patients heal within 4 weeks, a few need further treatment to heal. Pathological hypersecretory disease, Zollinger - Ellison syndrome: The dose of Rabeto-40 varies depending on the needs of each patient. Recommended initial dose: 60mg once daily. Some may consider taking smaller divided doses. The maximum dose is 100mg x 1 time/day or 60mg x 2 times/day. The course of treatment is prolonged until the clinical symptoms are gone. 3.2 Overdose and management There are currently no reports of clinical overdose with Rabeprazole. Because Rabeprazole is highly protein bound, it is not eliminated by dialysis. In case of Rabeprazole overdose, mainly symptomatic and supportive treatment, there is no specific antidote to Rabeprazole.
4. Some notes when using Rabeto-40
In the process of using Rabeto-40, it is necessary to pay attention to some of the following issues:Treatment response to Rabeprazole does not eliminate inherent gastric or esophageal cancer. Therefore, the possibility of malignancy should be excluded before using Rabeprazole. Patients treated for more than one year with rabeprazole should be monitored periodically. There is currently insufficient clinical experience with the use of rabeprazole in children under 12 years of age. Elderly patients, renal impairment: No dose adjustment is required for elderly, renally impaired patients. Impaired liver function: some cases appear abnormal liver enzymes after taking the drug. In the absence of other causes, these enzyme disturbances are not serious and resolve with discontinuation of Rabeprazole. No dose adjustment of Rabeto 40 is required in patients with mild to moderate hepatic impairment. Due to the lack of clinical data on the use of rabeprazole for the treatment of patients with severe hepatic impairment, extreme caution must be exercised when administering rabeprazole for the first time to this population. Rabeprazole should be used with caution due to the risk of cross-reactivity with other proton pump inhibitors or Benzimidazole derivatives when used as an alternative. As with other proton pump inhibitors, rabeprazole may increase the risk of gastrointestinal infections with Campylobacter, Salmonella and Clostridium difficile. Ability to drive, operate machines: Undesirable effects when taking Rabeto 40 such as drowsiness, headache may affect alertness. When taking Rabeprazole should not drive or operate machinery. Pregnancy: Rabeto 40 is contraindicated because there are no adequate studies on the safety of the drug in pregnant women. Lactation: Studies in mice have shown that the drug may be excreted in human milk. Rabeprazole should be used with caution in this population.
5. Undesirable effects when using Rabeto 40
The most common adverse reactions reported during clinical trials were: headache, asthenia, abdominal pain, diarrhea, flatulence, rash and dry mouth. Most of the symptoms appear transient, mild to moderate.
Some less common side effects when using Rabeto 40 are: dizziness, insomnia, infection, indigestion, muscle and joint pain, increased liver enzymes, erythema, leukopenia, thrombocytopenia, leukocytosis glomerulonephritis, hypertension, hepatitis, jaundice, hepatic encephalopathy.
6. Drug interactions
Warfarin: An increase in INR and prothrombin time has been reported in 6 patients receiving proton pump inhibitors, in which rabeprazole and Warfarin were co-administered. Cyclosporin: Studies have shown that Rabeprazole inhibits the metabolism of Cyclosporin. Gastric pH-dependent compounds for absorption: Rabeprazole causes prolonged inhibition of gastric acid secretion, which may cause interactions with compounds that depend on gastric pH for absorption. It is necessary to monitor the patient when taking Rabeprazole and Ketocomazol and Digoxin concomitantly. Atazanavir: Proton pump inhibitors can significantly increase Atazanavir plasma concentrations when co-administered with rabeprazole, reducing the therapeutic effect. Rabeprazole may increase the concentration or effect of drugs with substrates CYP2C8 (high risk), CYP2C19, Saquinavir, Methotrexate. Do not use Rabeprazole with Posaconazole, Nelfinavir, Delavirdin, Erlotinib simultaneously. Concomitant administration of rabeprazole with antacids did not produce clinically relevant changes in plasma concentrations of rabeprazole. Rabeto 40 is a proton pump inhibitor (PPI), which reduces gastric acid secretion. It is indicated for the treatment of gastroesophageal reflux disease with or without ulceration or ulceration (GERD), acute peptic ulcer. To ensure the effectiveness of treatment, patients need to strictly follow the instructions of the doctor or pharmacist.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.
Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.
